Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2026

Conditions
Diabetic PatientsAcute Myocardial Infarction
Interventions
DRUG

Semaglutide

After randomization, each patient will receive four blisters of 3 mg tablets (semaglutide or placebo) and four blisters of 7 mg tablets (semaglutide or placebo), to be taken before breakfast. After 60 days, the patient will receive a 14 mg dose (a total of 16 blisters with 7 tablets each). The possibility of maintaining the 14 mg dose of the study drug or reducing it to 7 mg will be evaluated depending on side effects and tolerability.

Trial Locations (1)

05403-900

ARO (Academic Research Organization), São Paulo

All Listed Sponsors
lead

University of Sao Paulo General Hospital

OTHER

NCT06557811 - Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction | Biotech Hunter | Biotech Hunter